DESCRIPTION NX-13 is a first-in-class, orally active and gut-restricted agent that selectively targets and activates the NLRX1 pathway to induce immunometabolic changes. NX-13 results in lower inflammation and responses in inflammatory bowel disease. NX-13 can be used for the research of crohn's disease and ulcerative colitis[1][2].

DESCRIPTION Amelenodor (NX-13) is triphenyl compound that is predicted to exhibit gut-selective distribution with limited systemic exposure. It functions as an agonist of the NOD-like receptor family protein NLR family member X1 (NLRX1) , and is proposed for clinical anti-inflammatory potential. NX-13 and its therapeutic uses are claimed in patent WO2020010132A1 . (GtoPdb)

DESCRIPTION NX-13 is an orally active, gut-restricted, compound that targets NLRX1. NX-13 is a small molecule compound that reduces inflammation and the therapeutic response to inflammatory bowel disease (IBD) by targeting and activating NLRX1 to induce changes in immune metabolism. NX-13 is safe and well tolerated in rats at oral doses up to 1000 mg/kg, with a good local pharmacokinetic profile of the gastrointestinal tract and is a candidate compound for the treatment of Crohn's disease and ulcerative colitis.NX-13 is a first-in-class, orally active and gut-restricted agent that selectively targets and activates the NLRX1 pathway to induce immunometabolic changes. (TargetMol Bioactive Compound Library)